Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Demographic, clinical and laboratory characteristics of the study cohorts

From: Transcription factor motif enrichment in whole transcriptome analysis identifies STAT4 and BCL6 as the most prominent binding motif in systemic juvenile idiopathic arthritis

Patient Cohort I (n = 6) Cohort II (n = 8)
Active disease, systemic
Cohort II (n = 5)
Active disease, polyarticular
Cohort II (n = 8)
Inactive disease
Gender 5 male, 1 female 5 male, 3 female 2 male, 3 female 5 male, 3 female
Age at diagnosis, years (median, range) 5.3 (1.8–12.9) 6.8 (0.4–17.4) 6.0 (0.5–15.3) 3.5 (0.4–9.7)
Time since first symptoms (median, range) 71 days (47–107 days) 18.6 months (1.6–109.7 months) 86.9 months (7.4–198.3 months) 105.1 months (52.6–195.8 months)
Number of active joints (median, range) 2 (1–18) 3.5 (0–10) 3 (2–4) 0 (0–0)
Platelet count (median, range) 520,500/mm3 (474,000–557,000/mm3) 352,000/mm3 (151,000–649,000/mm3) 276,000/mm3 (195,000–395,000/mm3) 306,500/mm3 (208,000–394,000/mm3)
Rheumatoid factor, negative 6/6 (100%) 8/8 (100%) 5/5 (100%) 8/8 (100%)
Ferritin, μg/l (median, range) 414 (32–1785 ) 754 (234–9980 μg/l) n.d. n.d.
C-reactive protein, mg/dl (median, range) 11.84 (4.87–25.6) 3.65 (1.10–26.4) 0.07 (0.03–6.57) 0.11 (0.03–0.63)
Initial prednisolone dose, mg/kg (median, range) 1.6 (0–2.08) n.a. n.a. n.a.
Initial anakinra dose, mg/kg (median, range) 1.63 (1.02–2.5) n.a. n.a. n.a.
  1. n.a. not applicable, n.d. not determined